Galectin-3: clinical utility and prognostic value in patients with heart failure
Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available abo...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-02-01
|
| Series: | Research Reports in Clinical Cardiology |
| Online Access: | http://www.dovepress.com/galectin-3-clinical-utility-and-prognostic-value-in-patients-with-hear-a12144 |
| Summary: | Frank KramerClinical Sciences, Global Biomarker Strategy and Development, Bayer HealthCare, Wuppertal, GermanyAbstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 was assessed as a biomarker of heart failure. In addition, most relevant information available about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context of heart failure.Keywords: biomarker, cardiovascular disease, therapy monitoring, prediction of outcome, patient stratification |
|---|---|
| ISSN: | 1179-8475 |